Company Encyclopedia
View More
name
Dimerix Limited
DXB.AU
News
View More

Dimerix Limited (DXB) Receives a Buy from Petra Capital

According to TipRanks, Jain is a 5-star analyst with an average return of 35.1% and a 45.95% success rate. Jain covers the Healthcare sector, focusing on stocks such as Pharmaust Limited, Argenica Therapeutics Ltd, and Dimerix Limited. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dimerix Limited with a A$1.46 average price target.

Tip Ranks·
Tip Ranks·

BKI Investment And 2 Other ASX Penny Stocks To Consider

BKI Investment and two other ASX penny stocks are highlighted as potential investment opportunities amid a positive market outlook. BKI Investment Company Limited, with a market cap of A$1.46 billion, shows financial stability but faces concerns over its dividend sustainability. Dimerix Limited, a biopharmaceutical firm, remains pre-revenue but has a secure cash runway. Kingsgate Consolidated Limited, focused on gold and silver mining, reported revenue growth but a decline in net income. Investors are encouraged to explore these stocks for potential value and growth.

Simplywall·
Simplywall·

Dimerix Limited Reports Significant Revenue Growth Despite Losses

Dimerix Limited (AU:DXB) reported a 914% increase in revenue to $5.9 million for the year ending June 30, 2025, despite a loss of $13.25 million, which is a 22% improvement from the previous year. The company did not declare dividends and continues to invest in its product development pipeline in the biotechnology sector. Analysts rate the stock as a Buy with a price target of A$1.58. Dimerix focuses on developing therapies for kidney disease and other chronic conditions.

Tip Ranks·
Tip Ranks·

Dimerix Limited Issues New Shares to Optimize Capital Structure

Dimerix Limited (AU:DXB) has announced the issuance of 41,710 fully paid ordinary shares following the cashless exercise of 250,000 unlisted options. This move aims to optimize the company's capital structure and enhance shareholder value, in compliance with the Corporations Act. The latest analyst rating for Dimerix stock is a Buy, with a price target of A$1.33. Dimerix operates in the biotechnology sector, focusing on innovative therapies for unmet medical needs, particularly in kidney disease and inflammatory conditions.

Tip Ranks·
Tip Ranks·

Dimerix Limited Announces New Securities Quotation on ASX

Dimerix Limited (AU:DXB) has announced the issuance of 1,250,448 ordinary fully paid securities, which will be quoted on the ASX under the code DXB. This reflects the exercise of options or conversion of convertible securities, potentially enhancing the company's market presence and investment opportunities. The latest analyst rating for Dimerix Limited stock is a Buy with a price target of A$1.36. The company operates in the biotechnology sector, focusing on innovative therapies for unmet medical needs, with a current market cap of A$355.1M.

Tip Ranks·
Tip Ranks·